Use of hydroxyurea in French-speaking Sub-Saharan Africa
HematologiaResumo original em inglês
O que aconteceu
The hydroxyurea is a save, affordable and essential medicine for sickle cell disease (SCD), reducing painful crises and mortality. To foster the prescription of hydroxyurea for patients with SCD in sub-Saharan African countries, the scientific advisory board of Drep.Afrique, a non-governmental organization dedicated to SCD in Africa, has developed a therapeutic guideline well suited to conditions on the ground. These guidelines answer three essential questions: which patients should be prioritized for treatment with hydroxyurea, which dose should be used, and what follow-up should be implemented in those low-resources countries? The guidelines are given as in a concise document for easy use by practitioners on the ground, available in English and in French.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Use of hydroxyurea in French-speaking Sub-Saharan Africa
Jean-Benoît Arlet, Françoise Bernaudin, Indou Deme-Ly, Binta Coulibaly, Anne Corbasson, Ibrahima Diagne, Dapa Diallo, Saliou Diop, Charlotte Eposse, Frédéric Galacteros et al.
Descritores MeSH
- Anemia, Sickle Cell
- Antisickling Agents
- Hydroxyurea
- Humans
- Africa South of the Sahara
Veja também
Estudos relacionados
- Association of hydroxyurea use and sickle cell retinopathy: A systematic review and meta-analysis
- Impact of telehealth on hydroxyurea adherence and clinical outcomes in sickle cell disease management: A systematic review and meta-analysis
- The Indian experience with hydroxyurea in sickle cell disease: A 25-year systematic review
- Reproductive function and sperm parameters in men with sickle cell disease: a systematic review